These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35578928)

  • 1. [Hematologic Malignancies/Pediatric Malignancies Molecular Targeted Therapies for Acute Myeloid Leukemia].
    Yano S
    Gan To Kagaku Ryoho; 2022 May; 49(5):534-535. PubMed ID: 35578928
    [No Abstract]   [Full Text] [Related]  

  • 2. Chemotherapy and Beyond: Infections in the Era of Old and New Treatments for Hematologic Malignancies.
    Atkins S; He F
    Infect Dis Clin North Am; 2019 Jun; 33(2):289-309. PubMed ID: 30935703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies.
    Kurtz SE; Eide CA; Kaempf A; Khanna V; Savage SL; Rofelty A; English I; Ho H; Pandya R; Bolosky WJ; Poon H; Deininger MW; Collins R; Swords RT; Watts J; Pollyea DA; Medeiros BC; Traer E; Tognon CE; Mori M; Druker BJ; Tyner JW
    Proc Natl Acad Sci U S A; 2017 Sep; 114(36):E7554-E7563. PubMed ID: 28784769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shutting the gate: targeting endocytosis in acute leukemia.
    Tremblay CS; Ting SB; McCluskey A; Robinson PJ; Curtis DJ
    Exp Hematol; 2021 Dec; 104():17-31. PubMed ID: 34563604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hematologic Malignancies Pipeline.
    Oncology (Williston Park); 2020 Oct; 34(10):430-431. PubMed ID: 33058110
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeting MCL-1 in hematologic malignancies: Rationale and progress.
    Wei AH; Roberts AW; Spencer A; Rosenberg AS; Siegel D; Walter RB; Caenepeel S; Hughes P; McIver Z; Mezzi K; Morrow PK; Stein A
    Blood Rev; 2020 Nov; 44():100672. PubMed ID: 32204955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of molecular targeted therapy for hematological disorder in the era of genomic drug discovery].
    Yoshimi A; Kurokawa M
    Nihon Rinsho; 2014 Jun; 72(6):1005-11. PubMed ID: 25016796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-Centered Insights on Treatment Decision Making and Living with Acute Myeloid Leukemia and Other Hematologic Cancers.
    Crawford R; Sully K; Conroy R; Johnson C; Doward L; Bell T; Welch V; Peloquin F; Gater A
    Patient; 2020 Feb; 13(1):83-102. PubMed ID: 31456136
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates on Hematologic Malignancies in the Older Adult: Focus on Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Multiple Myeloma.
    Huang LW; Wong SW; Andreadis C; Olin RL
    Curr Oncol Rep; 2019 Mar; 21(4):35. PubMed ID: 30848394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting CD123 in hematologic malignancies: identifying suitable patients for targeted therapy.
    Patnaik MM; Mughal TI; Brooks C; Lindsay R; Pemmaraju N
    Leuk Lymphoma; 2021 Nov; 62(11):2568-2586. PubMed ID: 33999767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic epigenetics: an emerging clinical approach to hematologic malignancies.
    Clin Adv Hematol Oncol; 2005 Mar; 3(3 Suppl 1):1-10; quiz 11-2. PubMed ID: 21438190
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hematologic malignancies/pediatric malignancies].
    Usui N
    Gan To Kagaku Ryoho; 2012 May; 39(5):731. PubMed ID: 22701898
    [No Abstract]   [Full Text] [Related]  

  • 13. The rise of apoptosis: targeting apoptosis in hematologic malignancies.
    Valentin R; Grabow S; Davids MS
    Blood; 2018 Sep; 132(12):1248-1264. PubMed ID: 30012635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies.
    Li L; Chai Y; Wu C; Zhao L
    Expert Rev Hematol; 2020 Dec; 13(12):1387-1396. PubMed ID: 33170753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision medicine and novel molecular target therapies in acute myeloid leukemia: the background of hematologic malignancies (HM)-SCREEN-Japan 01.
    Miyamoto K; Minami Y
    Int J Clin Oncol; 2019 Aug; 24(8):893-898. PubMed ID: 31111287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Asparaginase in the treatment of non-ALL hematologic malignancies.
    Emadi A; Zokaee H; Sausville EA
    Cancer Chemother Pharmacol; 2014 May; 73(5):875-83. PubMed ID: 24515335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic molecular marker and molecular targeted-therapy in pediatric malignancies].
    Hayashi Y
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):194-202. PubMed ID: 17301526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary haematological malignancies in the BCIRG 001 study.
    Arslan C; Uslu R
    Lancet Oncol; 2013 Mar; 14(3):e87-8. PubMed ID: 23452357
    [No Abstract]   [Full Text] [Related]  

  • 19. Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies.
    Gozgit JM; Wong MJ; Wardwell S; Tyner JW; Loriaux MM; Mohemmad QK; Narasimhan NI; Shakespeare WC; Wang F; Druker BJ; Clackson T; Rivera VM
    Mol Cancer Ther; 2011 Jun; 10(6):1028-35. PubMed ID: 21482694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncology Conference Highlights, Q4.
    Leavitt J; DeVito T; Saleh N
    Oncology (Williston Park); 2019 Jan; 33(1):8-10. PubMed ID: 30731012
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.